Protalix Biotherapeutics Inc. (NYSE MKT:PLX; TASE: PLX) announced today that it has chosen Shlomo Yanai as chairman of its board of directors, effective on July 24, 2014. Interim chairman Zeev Bronfeld will remain a director of the company.
"The board of Protalix and myself are pleased to have Mr. Yanai join our board as chairman," Bronfeld said, "He brings extensive knowledge and vast experience from his years as CEO at Teva Pharmaceutical Industries and Makhteshim Agan, which will be helpful in further guiding Protalix. We look forward to his leadership as chairman."
"I am excited to join the Board of Protalix, and to be a part of the company's revolutionary approach to recombinant therapeutic proteins," Yanai said. "This is an exciting time for the company, as we will continue together our efforts to progress the promising pipeline coming from ProCellEx technology as well as building the market for Elelyso. I am enthusiastic about the future of Protalix and glad to be part of it."
"We are grateful to Mr. Bronfeld for his term as interim chairman, during which he lead the board through the commercialization launch process of Elelyso in several countries, and the continued expansion our pipeline. We are looking forward to continued growth of Protalix under Mr. Yanai's guidance," said Protalix president and CEO David Aviezer.
Yanai was president and CEO of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) from 2007 until 2012. Before that, he was the president and CEO of agri-chemicals company Makhteshim Agan Industries (now Adama).
Published by Globes [online], Israel business news - www.globes-online.com - on July 24, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013